Huhn Stephen L. 4
4 · Contineum Therapeutics, Inc. · Filed May 29, 2024
Insider Transaction Report
Form 4
Huhn Stephen L.
CMO & Sr VP, Clinical Dev.
Transactions
- Award
Stock Option (right to buy)
2024-05-24+100,000→ 100,000 totalExercise: $15.76Exp: 2034-05-23→ Class A Common Stock (100,000 underlying)
Footnotes (1)
- [F1]Options granted under the Issuer's 2024 Equity Incentive Plan. 25% of the option shares vest on April 5, 2025, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.